A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia
Latest Information Update: 04 Nov 2021
At a glance
- Drugs LCAR L10D (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
Most Recent Events
- 03 Nov 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 24 Sep 2019 New trial record